Life expectancy and cardiovascular mortality in persons with schizophrenia

  title={Life expectancy and cardiovascular mortality in persons with schizophrenia},
  author={Thomas Munk Laursen and Trine Munk-Olsen and Mogens Vestergaard},
  journal={Current Opinion in Psychiatry},
Purpose of review To assess the impact of cardiovascular disease on the excess mortality and shortened life expectancy in schizophrenic patients. Recent findings Patients with schizophrenia have two-fold to three-fold higher mortality rates compared with the general population, corresponding to a 10–25-year reduction in life expectancy. Although the mortality rate from suicide is high, natural causes of death account for a greater part of the reduction in life expectancy. The reviewed studies… 

Excess early mortality in schizophrenia.

The most urgent research agenda concerns primary candidates for modifiable risk factors contributing to this excess mortality, i.e., side effects of treatment and lifestyle factors, as well as sufficient prevention and treatment of physical comorbidity.

Life Expectancy and Death by Diseases of the Circulatory System in Patients with Bipolar Disorder or Schizophrenia in the Nordic Countries

Overall life expectancy was much lower among persons with bipolar disorder or schizophrenia, with life expectancy being from 11 to 20 years shorter than in the Nordic countries with well-developed welfare systems.

Mortality in schizophrenia: clinical and serological predictors.

Because cigarette smoking confers an almost 5-fold risk of mortality, smoking cessation is an urgent priority and having an elevated level of antibodies to Epstein-Barr virus and to Herpes Simplex virus type 1 are also significant predictors of death from natural causes.

Mortality in schizophrenia and bipolar disorder: Clinical and serological predictors

Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study.

Schizophrenia patients had markedly premature mortality, and the leading causes were ischemic heart disease and cancer, which appeared to be underdiagnosed.

Cardiovascular disease in patients with schizophrenia

Coordinated care between tertiary providers, general practitioners and primary health care professionals should monitor the physical health of people with psychosis or schizophrenia at least annually and treatment should be offered accordingly.

Increased Mortality in Schizophrenia Due to Cardiovascular Disease – A Non-Systematic Review of Epidemiology, Possible Causes, and Interventions

There is an urgent need to develop and implement effective programs to increase life expectancy in schizophrenia, and it is argued that mental health workers should be more involved in this important task.



Schizophrenia and increased risks of cardiovascular disease.

Twenty-five year mortality of a community cohort with schizophrenia

People with schizophrenia have a mortality risk that is two to three times that of the general population, and most of the extra deaths are from natural causes.

Cardiovascular aspects of antipsychotics.

  • T. Raedler
  • Medicine, Psychology
    Current opinion in psychiatry
  • 2010
More research is needed to better understand the relationship between schizophrenia, antipsychotic treatment and cardiovascular disease, and more effective treatment strategies need to be developed to reduce the burden of cardiovascular disease in schizophrenia.

The Epidemiology of Excess Mortality in People with Mental Illness

There is substantial excess mortality in people with mental illness for almost all psychiatric disorders and all main causes of death in developed countries, and whether it has changed over time is investigated.

Mortality in schizophrenia: a measurable clinical endpoint

Data suggest that the mortality gap with the general population increased from the 1970s but may have peaked in the mid-1990s and the main causes of mortality are suicide, cancer and cardiovascular disease, with evidence that cancer mortality rates are similar to cardiovascular mortality rates.

Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study.

The risk of CVD mortality in schizophrenia does not differ between clozapine and risperidone in adults despite known differences in risk profiles for weight gain and metabolic side effects, however, one cannot rule out an increased risk ofCVD mortality among those starting treatment at ages 55 years or older.